A new study reports that mice shed about 20% of their body weight and saw their breast cancer tumors decrease after getting ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

The explosive popularity of GLP-1 weight-loss medications such as Ozempic®, Wegovy®, and Mounjaro® has transformed obesity care and created an unexpected cosmetic challenge. Rapid fat loss can leave ...

* Researchers at the Danish Headache Center are testing semaglutide along with a very low calorie diet as a treatment for new ...

For weight loss, Mounjaro may be prescribed off-label for those with a body mass index (BMI) of 30 or more or 27 or more with at least one weight-related condition, such as high blood pressure ...

"The Mounjaro (tirzepatide) Patient Information Leaflet warns that hair loss is a common side effect in patients treated with ...

A woman is speaking out after her successful attempt to buy weight-loss drug Mounjaro by using a ‘before’ image of another ...

Mounjaro patients were also 2.6 times more likely to achieve 10% weight loss and 1.8 times more likely to lose 5% of their weight, according to Truveta, which was earlier reported on by CNBC.

She lost 17kg in just five months using the trending weight-loss drug Mounjaro — but what came next left her shocked and ...

Eli Lilly, Mounjaro’s manufacturer, also assessed the drug’s effects on weight loss in the SURMOUNT-1 trial, whose results made a splash at the American Diabetes Association meeting in June 2022.

While Mounjaro is a dual GIP/GLP-1 agonist, Ozempic and Wegovy are both GLP-1 agonists, known chemically as semaglutide, that are currently approved to treat Type 2 diabetes and weight loss ...